Literature DB >> 33488861

Urate crystal deposition in hyperuricemic children: a dual energy computed tomography study.

Qianqian Ying1, Jiapei Wang2, Yunyan Li2, Nan Sun3, Yazhen Di2, Mengjiao Shen2, Shiwei Fu1.   

Abstract

INTRODUCTION: The incidence of hyperuricemia (HUA) at younger ages is increasing along the coastal regions of China. This study aimed to compare the frequency of dual energy CT (DECT) urate crystal deposition between symptomatic hyperuricemic children and asymptomatic hyperuricemic children.
MATERIAL AND METHODS: Fifty-six hyperuricemic children were divided into a Joint Group (n = 33) and an Asymptomatic Group (n = 23) according to whether they had a history of arthritis symptoms, which includes rapid onset monoarthritis with intense pain and swelling. We analyzed DECT scans of their feet from the Joint Group and the Asymptomatic Group and compared their clinical features.
RESULTS: DECT urate deposits were observed in 28/33 (84.8%) children with symptomatic HUA and 14/23 (60.9%) with asymptomatic HUA. We found 60 areas of urate deposition in the Joint Group; DECT urate crystal deposition was most frequently observed in the first metatarsophalangeal (MTP) joint (30.0%), ankle joint (15.0%), and calcaneus (13.3%). 39 urate deposits were found in the Asymptomatic Group; DECT urate crystal deposition was most frequently observed in the calcaneus (25.6%), the first MTP joint (17.9%), and the first phalanx (15.4%).
CONCLUSIONS: Urate deposition can occur in children with HUA, and these deposits occur more frequently in hyperuricemic children with a history of arthritis symptoms. Also, the urate deposition in the first MTP joint and calcaneus was more prevalent than in other joints. It is important to give more attention to hyperuricemic children. Copyright:
© 2021 Termedia & Banach.

Entities:  

Keywords:  children; dual-energy computed tomography; hyperuricemia; joint injury; urate crystal

Year:  2021        PMID: 33488861      PMCID: PMC7811330          DOI: 10.5114/aoms/89835

Source DB:  PubMed          Journal:  Arch Med Sci        ISSN: 1734-1922            Impact factor:   3.318


Introduction

Hyperuricemia (HUA) can occur as a result of urate overproduction, urate underexcretion, or a combination of both. Uric acid is the end product of purine metabolism. Monosodium urate (MSU) crystals separate out when uric acid exceeds the urate solubility threshold, which promotes acute inflammation [1]. Gout is one result of HUA, and affects approximately 4% of adults in the USA according to the National Health and Nutrition Examination Survey (NHANES) [2]. With the improvement of our living standards and significant change of diet, the incidence of HUA at younger ages is increasing along the coastal regions of China [3, 4]. Meanwhile our previous research found that MSU crystal deposition can be observed in hyperuricemic children [5]. It suggests that some patients with HUA have developed joint disease, and it may significantly affect their quality of life. However, there is little research about MSU crystals in hyperuricemic children. The present research used dual-energy CT (DECT) to analyze the content of MSU crystals, and the data are used to compare the frequency of DECT urate crystal deposition in children with HUA.

Material and methods

Fifty-six children, including 42 boys and 14 girls aged from 5 to 17 (12.13 ±2.05) years, with HUA were prospectively recruited between August 2015 to February 2018 from the Department of Pediatric Rheumatoid Immunity (inpatient and outpatient), Ningbo, China. Clinical features, laboratory data and DECT scans of both feet were obtained from participants with HUA, defined as serum urate level above the normal range for age and sex. The pediatric reference ranges were used as follows: babies aged 1–12 months 80–500 μmol/l, children aged 1–10 years 120–320 μmol/l, boys aged 11–15 years 160–470 μmol/l for, and girls aged 11–15 years 140–350 μmol/l. For those aged above 15 years the normal adult range was used [6, 7]. We excluded participants who had secondary HUA such as renal insufficiency, medicine, hematologic diseases, hyperthyroidism, autoimmune disease, or cancer after radiotherapy or chemotherapy. Patients’ serum urate was 363–757 μmol/l when they underwent the foot DECT. Children with HUA were divided into two groups. Joint Group: 1) HUA; 2) A history of arthritis symptoms including sudden rapid onset monoarthritis with intense pain and swelling. Inquiring about the medical history, body examination and other assistant examination were used to exclude trauma, fracture, growing pain, tumor and leukemia, especially juvenile idiopathic arthritis. Asymptomatic Group: 1) HUA; 2) Without a history of arthritis symptoms. The study was approved by the Ethical Committee of the Ningbo Women and Children’s Hospital and informed consent was obtained from the parents. DECT scans of the feet were performed on a dual X-ray tube 128 detector row scanner (Somatom Definition, Siemens, Munich, Germany). The image reconstructions were done using proprietary software (Gout, Syngo CT Workplace, Siemens Medical Systems; Siemens, Munich, Germany). After cleaning their feet, all children had DECT scans of both feet. The scanning parameters were used as follows: tube A, 140 kV/55 mA; tube B, 80 kV/243 Ma, collimation 0.6 mm reconstructed to 0.75 mm thick slices. The setting of image reconstructions was used as follows: 80 kV X-ray: soft tissue 50 HU, ratio 1.25, minimum 150 HU, range 5, air distance 5, the 140 kV, X-ray: soft tissue 50 HU, minimum 500 HU, bone distance 5. There were two readers (one radiologist and one rheumatologist, both experienced in DECT assessment), blinded to all clinical variables, including duration and serum urate results. They independently evaluated the DECT scans for the presence and sites of urate deposition.

Statistical analysis

Statistical analysis was performed using SPSS 18.0. Means with SD, median (range: max.–min.), percentages were used to describe the clinical characteristics of children. Differences between groups were analyzed by the χ2 test and t test, with p < 0.05 for the difference indicating statistical significance.

Results

Clinical characteristics of children with HUA

Table I shows the 56 children’s clinical features. There were no significant difference in age, gender, or body mass index (BMI) between the two groups. Mean BMI of all children was 23.12 kg/m². There were 12 obese children in the Joint Group, and 9 in the Asymptomatic Group according to age- and sex-specific BMI cutoff points for overweight and obese in Chinese children established by the Group of China Obesity Force [8]. Twenty-five (75.8%) patients in the Joint Group and 19 (82.6%) patients in the Asymptomatic Group had a serum urate level above 420 μmol/l. Mean disease duration in the Joint Group was 13.55 weeks. Four children in the Joint Group had a family history of gout or HUA, and two were sisters. Nine children in the Joint Group and 4 in the Asymptomatic Group were on urate-lowering therapy by benzbromarone and colchicine.
Table I

Clinical features and DECT MSU deposition rate of participants

ParameterJoint group, n = 33Asymptomatic group, n = 23P-value
Age [years]12.18 ±1.81; 13 (8)12.0 ±2.40; 12 (12)t = 0.246, p = 0.807
Gender, n (%):χ² = 0.025, p = 0.875
 Boy25 (75.8)17 (73.9)
 Girl8 (24.2)6 (39.1)
BMI [kg/m²]22.80 ±5.47; 22.23 (20.77)23.58 ±4.73; 23.08 (18.19)p = 0.582
Serum urate [μmol/l]465.61 ±84.26; 448 (388)466.52 ±59.66; 472 (24)
UA ≥ 420 μmol/l, n (%)25 (75.8)19 (82.6)
Positive rate n (%):χ² = 4.156, p = 0.041
 Positive28 (84.8)14 (60.9)
 Negative5 (15.2)9 (39.1)
HUA duration [weeks]13.55 ±22.51NA
Family history, n (%)4 (14.8%)1 (4.3%)

Unless specified, data are presented as mean ± SD; median (range: max.–min.), BMI – body mass index.

Clinical features and DECT MSU deposition rate of participants Unless specified, data are presented as mean ± SD; median (range: max.–min.), BMI – body mass index.

DECT MSU deposition in children with HUA

In the Joint Group, DECT MSU deposits were found in 28 (84.8%) children, and 14 (60.9%) children in the Asymptomatic Group (Table I). In total, 99 areas of urate deposition were observed in all participants. We found 60 areas of urate deposition in the Joint Group; DECT urate crystal deposition was most frequently observed in the first metatarsophalangeal (MTP) joint (30.0%), ankle joint (15.0%), and calcaneus (13.3%). Ninety-nine areas of urate deposition were found in the Asymptomatic Group; DECT urate crystal deposition was most frequently observed in the calcaneus (25.6%), the first MTP joint (17.9%), and the first phalanx (15.4%) (Table II, Figure 1).
Table II

Sites of urate deposition in HUA children

GroupData1st MTP jointOther MTP joint1st metatarsusOther metatarsus1st phalanxOther phalanxCalcaneus
Joint group (n = 33)MSU crustal18 (30.0%)1 (1.6%)3 (5.0%)4 (6.7%)2 (3.3%)2 (3.3%)8 (13.3%)
Patients13 (46.4%)1 (3.6%)2 (7.1%)2 (7.1%)2 (7.1%)2 (7.1%)6 (21.4%)
Asymptomatic group (n = 23)MSU crustal7 (17.9%)2 (5.1%)2 (5.1%)1 (2.6%)6 (15.4%)2 (5.1%)10 (25.6%)
Patients5 (35.7%)2 (14.3%)2 (14.3%)1 (7.1%)5 (35.7%)2 (14.3%)7 (50.0%)
GroupDataTalusAnkleDistal tibiaOther sitesSoft tissueErosionSum
Joint group (n = 33)MSU crystal5 (8.3%)9 (15.0%)2 (3.3%)4 (6.7%)1 (1.6%)1 (1.6%)60
Patients3 (10.7%)7 (25.0%)1 (3.6%)3 (10.7%)1 (3.6%)1 (3.6%)28
Asymptomatic group (n = 23)MSU crystal2 (5.1%)2 (5.1%)3 (7.7%)2 (5.1%)0 (0)0 (0)39
Patients1 (7.1%)2 (14.3%)2 (14.3%)2 (14.3%)0 (0)0 (0)14

MTP – metatarsophalangeal, MSU crystal – areas of MSU crystal deposition.

Figure 1

A, B – 10-year-old boy, HUA with left foot hallux swelling and pain. A – Three dimensional fusion, B – two dimensional coronal images show MSU crystal deposits (green) of the left metatarsals (arrows), and bone erosion. C, D – 10-year-old girl, asymptomatic HUA: C – the right foot, D – the left foot. Three dimensional fusion images show MSU crystal deposits of the right navicular bone, the right first metatarsal and lower end of left tibia and fibula, left calcaneus

Sites of urate deposition in HUA children MTP – metatarsophalangeal, MSU crystal – areas of MSU crystal deposition. A, B – 10-year-old boy, HUA with left foot hallux swelling and pain. A – Three dimensional fusion, B – two dimensional coronal images show MSU crystal deposits (green) of the left metatarsals (arrows), and bone erosion. C, D – 10-year-old girl, asymptomatic HUA: C – the right foot, D – the left foot. Three dimensional fusion images show MSU crystal deposits of the right navicular bone, the right first metatarsal and lower end of left tibia and fibula, left calcaneus

Discussion

Genetic enzyme defect, purine-rich foods and reduced renal uric acid clearance are the common risk factors for HUA [9]. We used to consider HUA as relatively rare in children when compared with adults. In our preliminary study, between June 2012 and October 2013, the incidence of HUA was 9.04% (2099/23217) of children in Ningbo Women and Children’s Hospital [4]. In Taiwan, China, the contemporary prevalence of HUA is 35.2% in children of Taiwan aborigines [10]. The results of studies seem to suggest that HUA prevalence is increasing in children. HUA is associated with kidney disease, cardiovascular disease and joint disease [6, 11, 12]. MSU crystallization can occur in children’s joints with the condition progress, causing gouty arthritis and joint deformities after a series of pathophysiological changes. The present study did not reveal any significant differences in age and sex, which may be because the sample size was too limited to get accurate results. The relationship between age, sex and hyperuricemia in children needs further investigation. In our study, we found that hyperuricemic children had significantly higher BMI than the normal range. Similar findings have been reported, indicating that BMI is related to uric acid concentrations [10, 13]. The prevalence of HUA and metabolic syndrome in children with overweight and obesity is high [14, 15]. It is difficult to interpret the relationship between the uric acid concentrations and DECT MSU deposition in hyperuricemic children, because 9 children in the Joint Group and 4 in the Asymptomatic Group were on urate-lowering therapy. In addition, we observed that 5 children with HUA had a family history of gout or HUA, and two were sisters. Childhood HUA is associated with genetic factors [16-18], and it was reported that the heritability estimate for serum uric acid was 39.9% [19]. The presence of negatively birefringent needle-shaped crystals in the synovial fluid under a microscope is used as a gold standard of gout [20]. However, this is an invasive procedure and not easy to use in hyperuricemic children. DECT can identify MSU crystals, used as an advanced imaging method in the clinical treatment of gout and HUA in adults [21]. Moreover, DECT-detected MSU crystal deposition has been included in the 2015 American College of Rheumatology and the European League Against Rheumatism gout classification criteria [22]. Our research revealed that DECT can also identify MSU crystals in children with HUA. This is helpful to make up for the insufficiency of clinical diagnosis and to evaluate the condition of the children. In our study, the positive rate of MSU crystals was 84.8% in the Joint Group, and one child showed bone erosion under DECT. It indicated that bone erosion can happen in hyperuricemic children like in adults with gout, which was lower than the erosion rate in adults with gout [23]. This may be related to the short time for MSU crystal deposition and thicker articular cartilage in children [24]. The positive rate of MSU crystals was 60.9% in the Asymptomatic Group. The data show that the MSU crystals appear before the joint symptoms. DECT can help us to find out whether the patients have MSU crystals, and can analyze the distribution and features of urate crystals around the feet in hyperuricemic children. Then we can implement intervention measures timely (e.g. low purine food or more water) according to the DECT results. Regular follow-up was carried out for these children to observe their uric acid levels and MSU crystal deposition, to research the relationship between the uric acid levels and joint symptoms in hyperuricemic children in the future. Our data indicate that the most common area of deposition in symptomatic hyperuricemic children was the first metatarsophalangeal (MTP) joint (18/60), and in asymptomatic hyperuricemic children was the calcaneus (10/39), which was similar to Huppertz A’s study in adults with gout [25]. This could be because the first MTP joint and calcaneus are dealing with an increase in weight load. Fewer blood vessels around and lower PH make this area more susceptible to MSU crystals being separated out here. Moreover, nerve endings distributed around the first MTP joint were more numerous than at the calcaneus, so it had higher sensitivity of inflammation and stimulation. The limitation of our study was that we did not obtain patients’ synovial fluid, which should be looked at under a microscope, so we cannot calculate the sensitivity and specificity of DECT for diagnosing children’s gout. In conclusion, the present study shows that MSU crystal deposition can be detected by DECT and was observed in children with HUA. In addition, it provides a comparison between symptomatic and asymptomatic children, and revealed that deposits occur more frequently in symptomatic hyperuricemic children. More importance and attention should be put on hyperuricemic children.

Conflict of interest

The authors declare no conflict of interest.
  23 in total

1.  Identification of urate crystals in gouty synovial fluid.

Authors:  D J MCCARTY; J L HOLLANDER
Journal:  Ann Intern Med       Date:  1961-03       Impact factor: 25.391

2.  Serum uric acid concentrations and SLC2A9 genetic variation in Hispanic children: the Viva La Familia Study.

Authors:  V Saroja Voruganti; Sandra Laston; Karin Haack; Nitesh R Mehta; Shelley A Cole; Nancy F Butte; Anthony G Comuzzie
Journal:  Am J Clin Nutr       Date:  2015-01-28       Impact factor: 7.045

3.  The epidemiology of hyperuricemia in children of Taiwan aborigines.

Authors:  Chiu-Shong Liu; Tsai-Chun Li; Cheng-Chieh Lin
Journal:  J Rheumatol       Date:  2003-04       Impact factor: 4.666

4.  Urate crystals deposition in the feet of overweight juveniles and those with symptomatic hyperuricemia: a dual-energy CT study.

Authors:  Nan Sun; Shiling Zhong; Yunyan Li; Ling Wu; Yazhen Di
Journal:  J Pediatr Endocrinol Metab       Date:  2016-05-01       Impact factor: 1.634

5.  Elevated Interleukin 1β and Interleukin 6 Levels in the Serum of Children With Hyperuricemia.

Authors:  Yazhen Di; Jiapei Wang; Yuanling Chen; Nan Sun; Ling Wu; Xiahua Dai; Mengjiao Shen; Qianqian Ying; Shiwei Fu
Journal:  J Clin Rheumatol       Date:  2018-03       Impact factor: 3.517

6.  Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.

Authors:  Yanyan Zhu; Bhavik J Pandya; Hyon K Choi
Journal:  Arthritis Rheum       Date:  2011-10

Review 7.  Synovial fluid analysis.

Authors:  Eliseo Pascual; Vega Jovaní
Journal:  Best Pract Res Clin Rheumatol       Date:  2005-06       Impact factor: 4.098

8.  Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout.

Authors:  Chuan-Chin Lu; Shyi-Kuen Wu; Han-Yu Chen; Wei-Sheng Chung; Meng-Chih Lee; Chih-Jung Yeh
Journal:  J Rheumatol       Date:  2014-08-01       Impact factor: 4.666

9.  Metabolic syndrome in primary gout.

Authors:  Nicolás M González-Senac; Rebeca Bailén; Rosa J Torres; Eugenio de Miguel; Juan G Puig
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2014       Impact factor: 1.381

10.  Genetic variation underlying renal uric acid excretion in Hispanic children: the Viva La Familia Study.

Authors:  Geetha Chittoor; Karin Haack; Nitesh R Mehta; Sandra Laston; Shelley A Cole; Anthony G Comuzzie; Nancy F Butte; V Saroja Voruganti
Journal:  BMC Med Genet       Date:  2017-01-17       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.